# Certepetide PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/certepetide

> Certepetide, sponsored by LISATA THERAPEUTICS, INC. (LSTA): 6 recorded catalysts.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, half-year only, quarter only, exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | certepetide |
| Codes |  |
| Sponsor | LISATA THERAPEUTICS, INC. (LSTA) https://sec-api.dev/companies/lsta/catalysts |
| Indications | Cholangiocarcinoma |
| Modality | peptide |
| FDA designations | fast track, orphan |

## Timeline

### Apr 2023: trial start

- Status: completed. Date confidence: month. Stage: 1/2.
- First seen 2024-11-12, last confirmed 2025-01-23.
- Press release filed with the SEC (EX-99) (accession 0000320017-25-000004): "Timing: Enrollment commenced April 2023 Appendix 51 iLSTA: Phase 1b/2a trial in locally advanced PDAC with chemo & IO" https://www.sec.gov/Archives/edgar/data/320017/000032001725000004/lstacorporatepresentatio.htm
- Press release filed with the SEC (EX-99) (accession 0000320017-24-000057): "Timing: Enrollment commenced April 2023 Appendix 49 iLSTA: Phase 1b/2a trial in locally advanced PDAC with chemo & IO" https://www.sec.gov/Archives/edgar/data/320017/000032001724000057/lstacorporatepresentatio.htm

### Jan 2025: interim data readout

- Status: scheduled. Date confidence: month.
- First seen 2024-11-12, last confirmed 2024-11-12.
- Press release filed with the SEC (EX-99) (accession 0000320017-24-000057): "Following the completion of enrollment in the fourth quarter of 2023, data from an interim analysis of the 95 Cohort A patients (single dose of certepetide administered with SoC) will be presented at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium in January of 2025." https://www.sec.gov/Archives/edgar/data/320017/000032001724000057/ex991earningsrelease3q24fi.htm

### mid-2025: topline data readout

- Status: scheduled. Date confidence: half.
- First seen 2024-11-12, last confirmed 2025-05-08.
- Press release filed with the SEC (EX-99) (accession 0000320017-25-000028): "The Company achieved complete enrollment in first-line CCA nearly six months ahead of plan, accelerating anticipated topline data readout to mid-2025." https://www.sec.gov/Archives/edgar/data/320017/000032001725000028/ex991earningsrelease1q25fi.htm
- Press release filed with the SEC (EX-99) (accession 0000320017-25-000010): "The Company achieved complete enrollment in first-line CCA nearly six months ahead of plan, accelerating anticipated topline data readout to mid-2025." https://www.sec.gov/Archives/edgar/data/320017/000032001725000010/ex991earningsrelease4q24.htm
- Press release filed with the SEC (EX-99) (accession 0000320017-24-000057): "The Company achieved complete enrollment in first-line CCA nearly six months ahead of plan, accelerating anticipated topline data readout to mid-2025." https://www.sec.gov/Archives/edgar/data/320017/000032001724000057/ex991earningsrelease3q24fi.htm

### Q4 2025: topline data readout

- Status: scheduled. Date confidence: quarter.
- First seen 2025-08-07, last confirmed 2025-11-06.
- Press release filed with the SEC (EX-99) (accession 0000320017-25-000069): "The Company achieved complete enrollment in first-line CCA nearly six months ahead of plan, accelerating anticipated topline data readout to fourth quarter of 2025." https://www.sec.gov/Archives/edgar/data/320017/000032001725000069/ex991earningsrelease3q25.htm
- Press release filed with the SEC (EX-99) (accession 0000320017-25-000059): "The Company achieved complete enrollment in first-line CCA nearly six months ahead of plan, accelerating anticipated topline data readout to fourth quarter of 2025." https://www.sec.gov/Archives/edgar/data/320017/000032001725000059/ex991earningsrelease2q25.htm

### April 5, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 2. Indication: Cholangiocarcinoma; Gallbladder Cancer; Gallbladder Carcinoma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05712356 (A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-04-05 (ACTUAL); Lead Sponsor Lisata Therapeutics, Inc.; Results First Posted 2026-05-26." https://clinicaltrials.gov/study/NCT05712356

### May 26, 2026: topline data readout

- Status: completed. Date confidence: exact. Stage: 2. Indication: Cholangiocarcinoma; Gallbladder Cancer; Gallbladder Carcinoma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05712356 (A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-04-05 (ACTUAL); Lead Sponsor Lisata Therapeutics, Inc.; Results First Posted 2026-05-26." https://clinicaltrials.gov/study/NCT05712356?tab=results

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/certepetide.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Certepetide PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/certepetide

```bibtex
@misc{secapidev_pdufa_certepetide_20261116,
  title        = {Certepetide PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/certepetide}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_certepetide_20261116","title":"Certepetide PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/certepetide","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
